

EFFECTIVE DATE: 03/16/2010
POLICY LAST UPDATED: 02/03/2015

OVERVIEW

This policy documents the coverage determination for Adoptive Immunotherapy. The spontaneous regression of certain cancers, such as renal cell cancer or melanoma, supports the idea that a patient's immune system can delay tumor progression and, on rare occasions, can eliminate the tumor altogether. These observations have led to research interest in a variety of immunologic therapies designed to stimulate a patient's own immune system. Adoptive immunotherapy is a method of activating lymphocytes for the treatment of cancer and other diseases.

PRIOR AUTHORIZATION

Not Applicable

POLICY STATEMENT

BlueCHiP for Medicare and Commercial

Adoptive immunotherapy is not medically necessary as there is insufficient medical literature to support the efficacy of this treatment.

MEDICAL CRITERIA

Not Applicable

BACKGROUND

Adoptive immunotherapy uses "activated" lymphocytes as a treatment modality. Both nonspecific and specific lymphocyte activation are used therapeutically. Nonspecific, polyclonal proliferation of lymphocytes by cytokines (immune system growth factors), also called autolymphocyte therapy, increases the number of activated lymphocytes. Initially, this was done by harvesting peripheral lymphokine-activated killer cells and activating them *in vitro* with the T cell growth factor interleukin-2 (IL-2) and other cytokines. More recent techniques have yielded select populations of cytotoxic T lymphocytes with specific reactivity to tumor antigens. Peripheral lymphocytes are propagated *in vitro* with antigen-presenting dendritic cells that have been pulsed with tumor antigens. Alternatively, tumor-infiltrating lymphocytes (TIL) from the tumor biopsy are propagated *in vitro* with IL-2 and anti-CD3 antibody, a T cell activator. Expansion of TIL for clinical use is labor intensive and requires laboratory expertise. Only a few cancers are infiltrated by T cells in significant numbers; of these, TIL can be expanded in only approximately 50% of cases. These factors limit the widespread applicability of TIL treatment. Recently, cytokine-induced killer cells have recently been recognized as a new type of antitumor effector cells, which can proliferate rapidly *in vitro*, with stronger antitumor activity and broader spectrum of targeted tumor than other reported antitumor effector cells.

The major research challenge in adoptive immunotherapy is to develop immune cells with antitumor reactivity in quantities sufficient for transfer to tumor-bearing patients. In current trials, 2 methods are studied: adoptive cellular therapy (ACT) and antigen-loaded dendritic cell infusions.

ACT is "the administration of a patient's own (autologous) or donor (allogeneic) anti-tumor lymphocytes following a lymphodepleting preparative regimen." Protocols vary, but include these common steps:

1. lymphocyte harvesting (either from peripheral blood or from tumor biopsy)
2. propagation of tumor-specific lymphocytes *in vitro* using various immune modulators
3. selection of lymphocytes with reactivity to tumor antigens with ELISA
4. lymphodepletion of the host with immunosuppressive agents
5. adoptive transfer (ie, transfusion) of lymphocytes back into the tumor-bearing host

Dendritic cell-based immunotherapy uses autologous dendritic cells (ADC) to activate a lymphocyte-mediated cytotoxic response against specific antigen *in vivo*. ADCs harvested from the patient are either pulsed with antigen or transfected with a viral vector bearing a common cancer antigen. The activated ADCs are then transfused back into the patient, where they present antigen to effector lymphocytes (CD4+ T cells, CD8+ T cells, and in some cases, B cells). This initiates a cytotoxic response against the antigen and against any cell expressing the antigen. In cancer immunotherapy, ADCs are pulsed with tumor antigens; effector lymphocytes then mount a cytotoxic response against tumor cells expressing these antigens.

In an attempt to further regulate the host immune system, recent protocols use various cytokines (e.g., IL-7 and IL-15 instead of IL-2) to propagate lymphocytes. Protocols also differ in the extent of host lymphodepletion induced prior to transfusing the lymphocytes to the tumor-bearing host.

Clinical studies using adoptive immunotherapy are primarily small, early-stage investigations of novel immunologic treatments for a variety of cancers. Although there is some evidence of benefit with cytokine-induced killer cells for end points such as recurrence rate, improvement in overall survival has not been demonstrated. Additionally, available studies are from non-U.S. centers in heterogeneous patient populations, and have methodological shortcomings that limit conclusions. Studies of cytotoxic T lymphocytes, lymphokine-activated killer cells, tumor-infiltrating lymphocytes, autologous dendritic cells, and genetically engineered T cells suggest that some adoptive immunotherapies (e.g., autologous dendritic cells) may improve outcomes in some cancer types (e.g., glioblastoma multiforme). However, impact of adoptive immunotherapy on patient outcomes (e.g., increased survival, improved quality of life) has yet to be clarified in large, randomized, controlled trials. Specifically, high-quality trials with adequate follow up are needed to show that there is an advantage for adoptive immunotherapy strategies in important end points for a significant cohort of cancer patients compared with standard treatments.

Therefore, adoptive immunotherapy is considered not medically necessary as there is insufficient medical literature to support the efficacy of this treatment.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement for applicable not medically necessary benefits/coverage.

CODING

Blue CHiP for Medicare and Commercial

The following code is considered not medically necessary:

S2107

RELATED POLICIES

None

PUBLISHED

Provider Update	April 2015
Provider Update	Aug 2014
Provider Update	May 2013
Provider Update	Apr 2012
Provider Update	Apr 2011

REFERENCES

1. Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). *J Cancer Res Clin Oncol*. Feb 2011; 137(2):305-310. PMID 20407789
2. Rosenberg SA, Nicholas PR, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. *Nat Rev Cancer*. 2008; 8(4):299-308.
3. Tang X, Liu T, Zang X, et al. Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis. *PLoS One*. 2013;8(5):e62847. PMID 23667530
4. Xie F, Zhang X, Li H, et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. *PLoS One*. 2012; 7(8):e42879. PMID 22916174
5. Zhong JH, Ma L, Wu LC, et al. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. *Int J Clin Pract*. Jan 2012; 66(1):21-27. PMID 22171902
6. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. *J Clin Oncol*. Mar 10 2014; 32(8):798-808. PMID 24344220
7. Chia WK, Teo M, Wang WW, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. *Mol Ther*. Jan 2014; 22(1):132-139. PMID 24297049
8. Ohtani T, Yamada Y, Furuhashi A, et al. Activated cytotoxic T-lymphocyte immunotherapy is effective for advanced oral and maxillofacial cancers. *Int J Oncol*. Nov2014;45(5):2051-2057. PMID 25120101
9. Schuessler A, Smith C, Beagley L, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. *Cancer Res*. Jul 1 2014; 74(13):3466-3476. PMID 24795429
10. Li JJ, Gu MF, Pan K, et al. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. *J Immunother*. Feb-Mar 2012; 35(2):189-195. PMID 22306907
11. Liu L, Zhang W, Qi X, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. *Clin Cancer Res*. Mar 15 2012; 18(6):1751-1759. PMID 22275504
12. Zhang Y, Wang J, Wang Y, et al. Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy. *Clin Dev Immunol*. 2013; 2013:195691. PMID 24382970
13. Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. *Cancer Immunol Immunother*. Dec 2012;61(12):2251-2259. PMID 22674056
14. Chung MJ, Park JY, Bang S, et al. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. *Cancer Immunol Immunother*. Sep 2014;63(9):939-946. PMID 24916038
15. Yu X, Zhao H, Liu L, et al. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. *J Clin Immunol*. Feb 2014;34(2):194-203. PMID 24337625

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

